Hugh Windom, MD
Allergy · Sarasota, FLNPI 1013902204
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 22.0%. Reporting peaked in 2022 at $11,641 and has fallen 59.0% since, to $4,772 in 2025. Among allergy clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 957 payments — averaging $38.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$8K
- Chiesi USA, Inc.$4K
- AstraZeneca$2K
- Sanofi$2K
- Octapharma USA, Inc.$2K
- GSK$2K
- plus $15K from 34 others
Across 466 payments — averaging $8202.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$910K
- AstraZeneca$565K
- Teva Pharmaceuticals USA, Inc.$357K
- Pfizer$317K
- GSK$309K
- Sanofi US Services Inc.$277K
- plus $1.1M from 10 others
What the payments were for
- Consulting fees$8,00922%
- Speaking & faculty fees$1,5004%
- Travel & lodging$5,37615%
- Food & beverage$21,61359%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,532 in reported general payments places this provider in the 90th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $652,422 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 180 | $135,782 |
| Breo ElliptaFluticasone/Vilanterol | 161 | $78,217 |
| Dupixent SyringeDupilumab | 17 | $62,209 |
| XolairOmalizumab | 13 | $34,193 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $18,954 |
| Spiriva RespimatTiotropium Bromide | 27 | $17,518 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $12,793 |
| Arnuity ElliptaFluticasone Furoate | 30 | $9,747 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $9,127 |
| DuleraMometasone/Formoterol | 23 | $8,548 |
| Azelastine Hcl | 230 | $5,627 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $5,573 |
| Qvar RedihalerBeclomethasone Dipropionate | 20 | $5,439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 191 | $4,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $1,288 | $652,42213 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,962 | $246,963417 claims |
| Boehringer IngelheimSpiriva Respimat | $69 | $17,51827 claims |
| AstraZenecaSymbicort | $2,436 | $12,79335 claims |
| MerckDulera | $56 | $8,54823 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $135 | $5,43920 claims |
| Hikma Pharmaceuticals USAEpinephrine | $36 | $1,71812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 allergy providers in Florida.
Other allergy in Sarasota
- Neha DunnSarasota$7K
- Eva BerkesSarasota$158
- Donna JamiesonSarasota$28
- Miguel LanzCoral Gables$778K
- Brett StanalandNaples$575K
- David RoseEglin Afb$253K
- Pavana BeerelliRockledge$61K
- Patrick de MarcoOrange Park$23K
- Mark MinorMelbourne$21K
- Alan KoterbaNorth Palm Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.